APOB and metabolic syndrome: The MD was −4.14 (95% CI: −11.32 to 3.05; p = 0.26; Figure 3E), demonstrating that a 4 mg dose of saroglitazar did not affect the apolipoprotein B level compared to that in the control group in patients with dyslipidemia.